Biotechnology company ImmunoMet Therapeutics Inc revealed on Monday the appointment of Dr Revati Shreeniwas as its chief medical officer.
As head of the medial department, Dr Shreeniwas will manage the clinical development programme for the company's lead investigational product Protein Complex 1 (PC1) inhibitor candidate, IM156, for idiopathic pulmonary fibrosis (IPF) and oncology indications.
Recently, Dr Shreeniwas has served on the faculty of Stanford University and Columbia Presbyterian Medical Center.
Previously, Dr Shreeniwas designed and implemented more than 50 US and international (Phase 1-4) clinical trials and been the clinical lead for regulatory interactions with the FDA and EMA.
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment